The c-Jun N-terminal kinase (JNK) pathway potentially links together the three major pathological hallmarks of Alzheimer's disease (AD): development of amyloid plaques, neurofibrillary tangles, and brain atrophy. As activation of the JNK pathway has been observed in amyloid models of AD in association with peri-plaque regions and neuritic dystrophy, as we confirm here for Tg2576/PS M146L transgenic mice, we directly tested whether JNK inhibition could provide neuroprotection in a novel brain slice model for amyloid precursor protein (APP)-induced neurodegeneration. We found that APP/amyloid β (Aβ)-induced neurodegeneration is blocked by both small molecule and peptide inhibitors of JNK, and provide evidence that this neuroprotection occurs downstream of APP/Aβ production and processing. Our findings demonstrate that Aβ can induce neurodegeneration, at least in part, through the JNK pathway and suggest that inhibition of JNK may be of therapeutic utility in the treatment of AD.
Introduction
Multiple and distinct pathologies characterize Alzheimer's disease (AD), including deposition of amyloid plaques, formation of neurofibrillary tangles and neurodegeneration (Huang and Jiang, 2009 ). Development of AD therapeutics has largely attempted to address these pathologies separately, but approaches that influence multiple pathologies may be advantageous. One pathway that potentially links all of the pathological hallmarks of AD is that through the c-jun Nterminal kinases (JNKs). The activation of JNKs leads to the phosphorylation of transcription factors controlling the apoptotic process (Dhanasekaran and Reddy, 2008) , thereby resulting in cell death in multiple neurodegenerative disorders (Bogoyevitch et al., 2004) . Furthermore, the JNK pathway can be activated by amyloid β (Aβ) peptides (Morishima et al., 2001 ) and has also been reported to regulate the phosphorylation of amyloid precursor protein (APP) leading to modulation of Aβ levels (Colombo et al., 2009 (Colombo et al., , 2007 .
Finally, there is strong evidence that JNKs can phosphorylate tau in vitro (Yoshida et al., 2004) .
The JNK pathway has been shown to be active in preclinical models of AD, including Tg2576 and Tg2576/PS1 P264L transgenic mice by biochemical and immunohistochemical analyses (Flood et al., 2002; Puig et al., 2004) . However, to date, there have been no reports on manipulation of the JNK pathway being directly tested in a model of AD to ask whether JNK activation may contribute to disease pathogenesis, and whether its inhibition may have therapeutic potential. Thus, in the present study, we first used a transgenic animal model of AD, with mutations in presenilin and APP resulting in excessive Aβ generation and amyloid plaque formation, to examine the potential association of JNK activation with amyloid histopathogenesis. We then directly examined whether inhibition of JNK pathways could provide benefit in a novel AD model system in which particlemediated gene transfer, or biolistics, is used to present an acute challenge of the amyloid cascade to ex vivo brain slice explants. This brain slice model has the ability to maintain the complex interplay among different resident cell types and their local connectivity, while retaining the ability to further investigate and manipulate the JNK pathways in the context of APP-induced neurodegeneration. Together, our findings from these in vivo and ex vivo models link amyloid, tau and neurodegenerative pathologies through the JNK pathway, and suggest that inhibition of JNK activity could provide therapeutic benefit in the context of AD. 
